Visualitza per autor "O’Shaughnessy, Joyce"
Ara mostrant els elements 1-5 d 5
-
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Fasching, Peter A.; Couch, Fergus; Delaloge, Suzette; labidi-galy, sana intidhar; O’Shaughnessy, Joyce; Balmaña, Judith (Springer, 2024-04) -
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
Huang, Min; Haiderali, Amin; Fox, Grace E.; Frederickson, Andrew; Cortés Castan, Javier; O’Shaughnessy, Joyce; Fasching, Peter A. (Springer, 2022-05) -
Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
O’Shaughnessy, Joyce; Cortés Castan, Javier; Twelves, Chris; Goldstein, Lori J.; Alexis, Karenza; Xie, Ran (Nature Research, 2020-07-08) -
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Dent, Rebecca; O’Shaughnessy, Joyce; Kim, Sung‑Bae; Isakoff, S. J.; Barrios, Carlos; Antunes de Melo Oliveira, Ana Mafalda; Turner, Nicholas (Springer, 2022-02) -
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Dieras, Veronique; Cortés Castan, Javier; Patt, Debra; Wildiers, Hans; O’Shaughnessy, Joyce; Zamora Adelantado, Esther; Rugo, Hope (Springer, 2020-11)